165 related articles for article (PubMed ID: 31874060)
1. Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).
Zagórska A
Expert Opin Ther Pat; 2020 Feb; 30(2):147-157. PubMed ID: 31874060
[No Abstract] [Full Text] [Related]
2. Experimental and investigational phosphodiesterase inhibitors in development for asthma.
Ntontsi P; Detta A; Bakakos P; Loukides S; Hillas G
Expert Opin Investig Drugs; 2019 Mar; 28(3):261-266. PubMed ID: 30678501
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
Kehler J
Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
[TBL] [Abstract][Full Text] [Related]
4. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
Chen J; Zook D; Crickard L; Tabatabaei A
Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.
Zagorska A; Partyka A; Bucki A; Gawalskax A; Czopek A; Pawlowski M
Curr Med Chem; 2018; 25(29):3455-3481. PubMed ID: 29521210
[TBL] [Abstract][Full Text] [Related]
7. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
9. Patented PDE10A inhibitors: novel compounds since 2007.
Kehler J; Kilburn JP
Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors.
Yu YF; Zhang C; Huang YY; Zhang S; Zhou Q; Li X; Lai Z; Li Z; Gao Y; Wu Y; Guo L; Wu D; Luo HB
ACS Chem Neurosci; 2020 Apr; 11(7):1058-1071. PubMed ID: 32105440
[TBL] [Abstract][Full Text] [Related]
11. The Construction and Application of a New Screening Method for Phosphodiesterase Inhibitors.
Gao C; Wang Z; Liu X; Sun R; Ma S; Ma Z; Wang Q; Li G; Zhang HT
Biosensors (Basel); 2024 May; 14(5):. PubMed ID: 38785726
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase regulation of alcohol drinking in rodents.
Logrip ML
Alcohol; 2015 Dec; 49(8):795-802. PubMed ID: 26095589
[TBL] [Abstract][Full Text] [Related]
15. Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
Chappie TA; Helal CJ; Hou X
J Med Chem; 2012 Sep; 55(17):7299-331. PubMed ID: 22834877
[No Abstract] [Full Text] [Related]
16. PDE inhibition and cognition enhancement.
Blokland A; Menniti FS; Prickaerts J
Expert Opin Ther Pat; 2012 Apr; 22(4):349-54. PubMed ID: 22475506
[No Abstract] [Full Text] [Related]
17. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
Amin HS; Parikh PK; Ghate MD
Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
[TBL] [Abstract][Full Text] [Related]
19. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
Kehler J; Nielsen J
Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterases in human spermatozoa and seminal fluid: Presence of an active PDE10A in human spermatozoa.
Maréchal L; Guillemette C; Goupil S; Blondin P; Leclerc P; Richard FJ
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):147-156. PubMed ID: 27836756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
